MA44056A - Anticorps anti-rispéridone et leur utilisation - Google Patents

Anticorps anti-rispéridone et leur utilisation

Info

Publication number
MA44056A
MA44056A MA044056A MA44056A MA44056A MA 44056 A MA44056 A MA 44056A MA 044056 A MA044056 A MA 044056A MA 44056 A MA44056 A MA 44056A MA 44056 A MA44056 A MA 44056A
Authority
MA
Morocco
Prior art keywords
risperidone
antibodies
risperidone antibodies
Prior art date
Application number
MA044056A
Other languages
English (en)
Inventor
Linda Colt
Thomas R Decory
Pieter Rik Haspeslagh
Eric Hryhorenko
Banumathi Sankaran
Theresa Tubbs
Maarten Vliegen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA44056A publication Critical patent/MA44056A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MA044056A 2015-12-17 2016-12-15 Anticorps anti-rispéridone et leur utilisation MA44056A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562268898P 2015-12-17 2015-12-17

Publications (1)

Publication Number Publication Date
MA44056A true MA44056A (fr) 2018-10-24

Family

ID=57708858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044056A MA44056A (fr) 2015-12-17 2016-12-15 Anticorps anti-rispéridone et leur utilisation

Country Status (8)

Country Link
US (2) US10444250B2 (fr)
EP (1) EP3390449A1 (fr)
JP (1) JP6949025B2 (fr)
CN (1) CN108431040B (fr)
AU (1) AU2016372069A1 (fr)
CA (1) CA3008809A1 (fr)
MA (1) MA44056A (fr)
WO (1) WO2017106501A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
CA2882489A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre des haptenes de paliperidone et leur utilisation
CN104755093B (zh) 2012-08-21 2018-11-16 詹森药业有限公司 奥氮平半抗原的抗体及其用途
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
AU2016370853A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
CN112730825B (zh) * 2020-12-17 2022-09-06 北京丹大生物技术有限公司 一种用于检测利培酮和/或9-羟基利培酮的检测试剂和检测试剂盒
CN115927347B (zh) * 2022-10-14 2026-01-16 杭州佰辰医学检验所有限公司 特异性结合利培酮的核酸适配体及衍生物、应用、试剂盒

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
ATE204385T1 (de) 1991-06-07 2001-09-15 Johnson & Johnson Clin Diag Immunoassays unter verwendung von markierten hapten-analogen
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
EP0582368B1 (fr) 1992-05-29 2001-01-24 Eli Lilly And Company Limited Dérivés de thienobenzodiazépine pour le traitement des troubles du système nerveux central
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
ATE410514T1 (de) 1994-06-10 2008-10-15 Oklahoma Med Res Found Calciumbindende rekombinante antikörper gegen protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
AU8148898A (en) 1997-06-23 1999-01-04 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
ATE492565T1 (de) 2002-01-31 2011-01-15 Randox Lab Ltd Immunogene, antikörper und konjugate für ketamin und dessen metaboliten
WO2003072736A2 (fr) 2002-02-21 2003-09-04 Duke University Reactifs et methodes therapeutiques de maladies auto-immunes
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
ATE380818T1 (de) 2002-03-28 2007-12-15 Lilly Co Eli Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
JP2005538108A (ja) 2002-07-29 2005-12-15 ポトマック， ファーマ， エルエルシー α−２アドレナリン作動性レセプターアンタゴニストと非定型抗精神病薬精神安定薬との抗精神病薬組み合わせ治療および組成物
ES2285227T3 (es) 2002-08-05 2007-11-16 Eli Lilly And Company Arilbenzodiazepinas sustituidas con piperazina.
US7271252B2 (en) 2003-04-22 2007-09-18 Roche Diagnostics Operations, Inc. Reagents for detecting efavirenz
WO2005000901A2 (fr) 2003-05-09 2005-01-06 Duke University Anticorps specifiques de cd20 et leurs methodes d'utilisation
JP5144930B2 (ja) 2003-08-18 2013-02-13 ハー・ルンドベック・アクチエゼルスカベット トランス−１−（６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジン
EP1664007B1 (fr) 2003-09-23 2009-12-23 Fermion Oy Procede de preparation de quetiapine
KR101255074B1 (ko) 2003-10-01 2013-04-16 아돌로 코포레이션 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
KR100931784B1 (ko) 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
AU2004298660B2 (en) 2003-12-12 2010-04-22 Abbott Rapid Diagnostics International Unlimited Company Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
JP4943144B2 (ja) 2004-04-26 2012-05-30 松山 隆美 葉酸リセプターベータ（ＦＲ−β）に対する単クローン抗体を含有する治療薬
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
US20080214808A1 (en) 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US20100061933A1 (en) 2006-10-20 2010-03-11 Naoki Kimura Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
CN101636182B (zh) 2006-10-25 2013-01-16 雷蒙特亚特特拉维夫大学有限公司 具有谷氨酸nmda活性的新型精神病治疗剂
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
CA2672581A1 (fr) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d'un tel anticorps
ES2405364T3 (es) 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
CN101600716A (zh) 2007-01-08 2009-12-09 阿特维斯集团公司 用于制备9-羟基-3-(2-氯乙基)-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮盐酸盐的改进方法
CN101245065B (zh) 2007-02-14 2010-05-19 江苏恩华药业股份有限公司 制备苯并异噁唑衍生物的方法及其中间体
MX2010003259A (es) 2007-09-27 2010-04-12 Novartis Ag Ensayo de monitoreo de farmacos.
NZ590563A (en) 2008-07-21 2012-06-29 Probiodrug Ag Diagnostic antibody assay
JP2011529923A (ja) 2008-08-06 2011-12-15 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
WO2010043893A1 (fr) 2008-10-14 2010-04-22 Astrazeneca Ab Composés hétéroaromatiques spirocycliques fusionnés pour traiter les infections bactériennes
US20100144781A1 (en) 2008-10-29 2010-06-10 Dong-Jing Fu Methods of treating psychosis and schizophrenia based on polymorphisms in the erbb4 gene
EP2194048A1 (fr) 2008-12-02 2010-06-09 Dirk Sartor Esters de nitrate pour le traitement de maladies vasculaires et métaboliques
NZ594071A (en) 2009-01-26 2013-01-25 Egalet Ltd Controlled release formulations comprising morphine sulphate for continuous treatment of pain
JP5986382B2 (ja) 2009-03-10 2016-09-06 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング癌ワクチン
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
ES2833035T3 (es) 2009-07-31 2021-06-14 Ascendis Pharma As Hidrogeles biodegradables insolubles en agua a base de polietilenglicol
WO2011021381A1 (fr) 2009-08-17 2011-02-24 株式会社未来創薬研究所 Composition pharmaceutique contenant un anticorps anti-hb-egf comme ingrédient actif
EP2485767A1 (fr) 2009-10-06 2012-08-15 Ascendis Pharma A/S Promédicaments à base de palipéridone liée à un support
EP2343296A1 (fr) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. Procédé pour la purification de la palipéridone
CA2785846C (fr) 2009-12-31 2015-07-07 Kempharm, Inc. Conjugues d'acides amines de quetiapine, procede de fabrication et d'utilisation de ceux-ci
SI2544536T1 (sl) 2010-03-11 2019-03-29 Kempharm, Inc. Maščobno kislinski konjugati kvetiapina proces za njih izdelavo in uporabo
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (fr) 2010-06-15 2011-12-22 The Regents Of The University Of California Procédé et dispositif pour la détection d'analytes
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
CA2802733C (fr) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Promedicaments de composes nh-acides : derives esters, carbonates, carbamates et phosphonates
WO2012003418A2 (fr) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Ligands fonctionnellement sélectifs des récepteurs d2 de dopamine
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2741779A1 (fr) 2011-08-12 2014-06-18 Ascendis Pharma A/S Promédicaments liés à des excipients hydrosolubles de forte charge
WO2013024048A1 (fr) 2011-08-12 2013-02-21 Ascendis Pharma A/S Promédicaments liés à des excipients polymériques hyperbranchés
WO2013088255A1 (fr) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Promédicaments de composés amine secondaires
MX2015002036A (es) 2012-08-16 2016-01-22 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
EP3492473B1 (fr) 2012-08-21 2025-07-30 Janssen Pharmaceutica NV Haptènes d'olanzapine
CN104755093B (zh) 2012-08-21 2018-11-16 詹森药业有限公司 奥氮平半抗原的抗体及其用途
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
CA2882489A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre des haptenes de paliperidone et leur utilisation
ES2822914T3 (es) 2012-08-21 2021-05-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
WO2014031668A2 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Anticorps dirigés contre la quétiapine et leur utilisation
TR201816416T4 (tr) * 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
CN104755928B (zh) 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
AU2013305965B2 (en) * 2012-08-21 2017-08-24 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
PT3663317T (pt) 2012-08-21 2023-01-23 Janssen Pharmaceutica Nv Anticorpos para haptenos de quetiapina e sua utilização
EP3556759B1 (fr) 2012-08-21 2023-11-29 Janssen Pharmaceutica NV Haptènes de palipéridone
TR201809424T4 (tr) * 2012-08-21 2018-07-23 Janssen Pharmaceutica Nv Risperidon ve paliperidon haptenleri.
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
CA2882557C (fr) 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptenes de la quetiapine destines a etre utilises dans des dosages immunologiques
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
AU2016370853A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof

Also Published As

Publication number Publication date
CN108431040B (zh) 2022-07-26
CA3008809A1 (fr) 2017-06-22
US10852313B2 (en) 2020-12-01
US20200033370A1 (en) 2020-01-30
US10444250B2 (en) 2019-10-15
CN108431040A (zh) 2018-08-21
US20170176473A1 (en) 2017-06-22
AU2016372069A1 (en) 2018-06-07
JP2019504013A (ja) 2019-02-14
JP6949025B2 (ja) 2021-10-13
WO2017106501A1 (fr) 2017-06-22
EP3390449A1 (fr) 2018-10-24

Similar Documents

Publication Publication Date Title
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
EP3572427A4 (fr) Anticorps ciblant bcma et son utilisation
EP3575318A4 (fr) Anticorps anti-pd-1 et son utilisation
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
EP3442567A4 (fr) Anticorps anti-psma et leur utilisation
MA46525A (fr) Anticorps anti-lag-3 et compositions
EP3334757A4 (fr) Anticorps anti-tigit
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3498840A4 (fr) Anticorps anti-lag-3
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
EP3297671A4 (fr) Anticorps anti-ror1
MA52285A (fr) Anticorps multispécifiques et leur utilisation
EP3302442A4 (fr) Formes galéniques et leur utilisation
EP3423089A4 (fr) Anticorps anti-tigit
EP3397276A4 (fr) Anticorps et conjugués de ceux-ci
PL3653221T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
EP3333192A4 (fr) Anticorps dirigé contre le glypican-3 et application associée
EP3265113A4 (fr) Anticorps anti-lilrb et leur utilisation pour détecter et traiter un cancer
EP3349787A4 (fr) Anticorps cd47 thérapeutiques
EP3307274A4 (fr) Anticorps anti-cd123 et conjugués de ceux-ci
MA47472A (fr) Anticorps
EP3492591A4 (fr) Anticorps anti-b7-h4
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation